|Privately held naamloze vennootschap; subsidiary|
|Ronald Brus (CEO), Jan Pieter Oosterveld (Chairman of the supervisory board)|
|Products||Vaccines and antibodies|
|Owner||Johnson & Johnson|
In September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine. J&J acquired the rest of the company in October 2010, taking its stake to over 95% by February 2011 and delisting the company from stock exchanges two months later.
- Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. Retrieved 28 September 2009.
- Solsman, Joan E. (17 February 2011). "J&J: Sufficient Number Of Crucell Holders Tender Shares". The Wall Street Journal. Dow Jones Newswires. Retrieved 27 February 2011.
- Gray-Block, Aaron (11 April 2011). "Crucell to be delisted after J&J buyout". Reuters. Retrieved 16 April 2011.